Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain-Reference-Cited by-同舟云学术

Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain

Published:2023-10 Issue:25 Volume:18 Page:1799-1813
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Sánchez-Dengra Bárbara¹^ORCID,Alfonso María²,González-Álvarez Isabel¹^ORCID,Bermejo Marival¹^ORCID,González-Álvarez Marta¹^ORCID,Martínez-Máñez Ramón²³⁴⁵

Affiliation:

1. Engineering: Pharmacokinetics & Pharmaceutical Technology Area, Miguel Hernandez University, San Juan Alicante, 03550, Spain

2. Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València, Universitat de València, Camino de Vera s/n, Valencia, 46022, Spain

3. Unidad Mixta UPV-CIPF de Investigación en Mecanismos de Enfermedades y Nanomedicina, València, Universitat Politècnica de València, Centro de Investigación Príncipe Felipe, València, 46012, Spain

4. Unidad Mixta de Investigación en Nanomedicina y Sensores, Universitat Politècnica de València, Instituto de Investigación Sanitaria La Fe, València, 46026, Spain

5. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, 28029, Spain

Abstract

Background: Glioblastoma is the most common and lethal brain cancer. New treatments are needed. However, the presence of the blood–brain barrier is limiting the development of new treatments directed toward the brain, as it restricts the access and distribution of drugs to the CNS. Materials & methods: In this work, two different nanoparticles (i.e., mesoporous silica nanoparticles and magnetic mesoporous silica nanoparticles) loaded with ponatinib were prepared. Results & conclusion: Both particles were characterized and tested in vitro and in vivo, proving that they are not toxic for blood–brain barrier cells and they increase the amount of drug reaching the brain when administered intranasally in comparison with the results obtained for the free drug.

Funder

Ministerio de Ciencia e Innovación

Fundacion Bienvenida Navarro-Luciano Tripodi

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2023-0131

Reference48 articles.

1. Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019) results. (2020). http://ghdx.healthdata.org/gbd-results-tool

2. Astrocyte elevated gene-1 as a novel therapeutic target in malignant gliomas and its interactions with oncogenes and tumor suppressor genes

3. American Association of Neurological Surgeons. Glioblastoma multiforme. www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme (2023).

4. Therapeutic nanoplatforms and delivery strategies for neurological disorders

5. Startoncology. Central nervous system gliomas (2016). www.startoncology.net/professional-area/cns-gliomas/?lang=en

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment;Biomedicines;2024-08-11

2. Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport;Pharmaceutics;2024-04-01